 |
6 Diseases |  |
0 Trials |
|
0 Trials |  |
44 News |  |
- | eltoprazine (DU 28853) / Amarantus BioSci, PsychoGenics, ReqMed
Preclinical, Journal: Eltoprazine modulated gamma oscillations on ameliorating L-dopa-induced dyskinesia in rats. (Pubmed Central) - May 1, 2023
The detection of enhanced PAC and functional connectivity of gamma-band oscillation can be used to guide and optimize deep brain stimulation parameters. Eltoprazine has potential clinical application for dyskinesia.
- || Clinical, Review, Journal: Levodopa-induced dyskinesia: a brief review of the ongoing clinical trials. (Pubmed Central) - Apr 28, 2022
Eltoprazine has potential clinical application for dyskinesia. No abstract available
- | eltoprazine (DU 28853) / Amarantus BioSci, PsychoGenics, ReqMed, preladenant (SCH 420814) / Merck (MSD)
Preclinical, Journal: Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT receptor agonist and A receptor antagonist. (Pubmed Central) - Feb 3, 2022
Finally, tyrosine hydroxylase and dopamine transporter examined to evaluate neurodegeneration, showed a significant equal decrease in all experimental groups. The present findings suggest that combination of l-dopa with eltoprazine and preladenant may be promising therapeutic strategy for delaying the onset of dyskinesia, preserving l-dopa efficacy and reducing neuroinflammation markers in nigrostriatal system of 6-OHDA-lesioned rats.
- | eltoprazine (DU 28853) / Amarantus BioSci, PsychoGenics, ReqMed
Journal: Eltoprazine prevents levodopa-induced dyskinesias by reducing causal interactions for theta oscillations in the dorsolateral striatum and substantia nigra pars reticulate. (Pubmed Central) - Dec 29, 2019
4) Chronic eltoprazine reduced BG theta activity in LID rats and normalized information flow directionality, relative to that in LID rats not given eltoprazine. These results indicate that dStr activity plays a determinative role in the causal interactions of theta oscillations and that serotonergic inhibition may suppress dyskinesia by reducing dStr-SNr theta activity and restoring theta network information flow.
- | eltoprazine (DU 28853) / Amarantus BioSci, PsychoGenics, ReqMed, Addyi (flibanserin) / Bausch Health
Journal: Technological prospection: Patents mapping involving compounds for the treatment of L-DOPA-induced dyskinesias. (Pubmed Central) - Dec 26, 2019
Thus, the present study aimed to prospect patents of alternative treatment strategies for L-DOPA-induced dyskinesias.Areas covered: This review covers the therapeutic patents published over the 2001-2019 period in the WIPO, INPI, and ESPACENET, which report treatment strategies for L-DOPA induced dyskinesias (LIDs).Expert opinion: In recent years, several pharmaceutical companies, as well as universities and researchers have tested effective compounds for LIDs treatment, showing substances that act on central pathways as antagonists and agonists of the serotonergic system, which may result in the key to onset of LIDs in animal models of PD. Future works aiming to elucidate the L-DOPA, Flibanserin, Eltoprazine, and Pridopidina mechanisms of action on the receptors of the serotonergic system and D receptors of the indirect pathway, will allow the development of effective therapies for LIDs.
- eltoprazine (DU 28853) / Amarantus BioSci, PsychoGenics, ReqMed, preladenant (SCH 420814) / Merck (MSD)
Neuroinflammation and activation of Zif-268 in dyskinetic 6-OHDA-lesioned rats is counteracted by association of a 5-HT1A/1B receptor agonist and an A2A receptor antagonist (Agora 3 West, Level 3) - Sep 24, 2019 - Abstract #MDSCongress2019MDS_1142;
Future works aiming to elucidate the L-DOPA, Flibanserin, Eltoprazine, and Pridopidina mechanisms of action on the receptors of the serotonergic system and D receptors of the indirect pathway, will allow the development of effective therapies for LIDs. The present findings suggest that combined administration of L-dopa with eltoprazine and preladenant may be a promising therapeutic strategy for treating motor symptoms, delaying the onset of dyskinesia and reducing the neuroinflammation response in PD.
- ||| eltoprazine (DU 28853) / Amarantus BioSci, PsychoGenics, ReqMed
Enrollment closed, Trial primary completion date: A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease Patients (clinicaltrials.gov) - Apr 23, 2016
P2, N=60, Active, not recruiting, Sponsor: Amarantus BioScience Holdings, Inc.
The present findings suggest that combined administration of L-dopa with eltoprazine and preladenant may be a promising therapeutic strategy for treating motor symptoms, delaying the onset of dyskinesia and reducing the neuroinflammation response in PD. Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Jun 2017
- eltoprazine (DU 28853) / Amarantus BioSci, PsychoGenics, ReqMed
Enrollment open: A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease Patients (clinicaltrials.gov) - Jun 7, 2015
P2, N=60, Recruiting, Sponsor: Amarantus BioScience Holdings, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Jun 2017 Not yet recruiting --> Recruiting
- | eltoprazine (DU 28853) / Amarantus BioSci, PsychoGenics, ReqMed
New P2 trial: A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease Patients (clinicaltrials.gov) - May 8, 2015
P2, N=60, Not yet recruiting, Sponsor: Amarantus BioScience Holdings, Inc.
- eltoprazine (DU 28853) / Amarantus BioSci, PsychoGenics, ReqMed
Trial completion, Enrollment change: Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults (clinicaltrials.gov) - Apr 14, 2015
P2, N=31, Completed, Sponsor: Amarantus BioScience Holdings, Inc.
Not yet recruiting --> Recruiting Recruiting --> Completed | N=50 --> 31
- | eltoprazine (DU 28853) / Amarantus BioSci, PsychoGenics, ReqMed
Enrollment open: Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults (clinicaltrials.gov) - Aug 16, 2011
P2, N=50, Recruiting, Sponsor: PsychoGenics Inc.
Recruiting --> Completed | N=50 --> 31 Not yet recruiting --> Recruiting